Shares in Roche fell over five percent after clinical trials revealed that its breast cancer drug giredestrant did not demonstrate efficacy in newly diagnosed patients when used in combination with Pfizer’s Ibrance. The late-stage trial failed to show significant disease progression benefits compared to standard hormonal therapy. Roche’s prior success with giredestrant had raised expectations, but analysts now express concerns about its market potential, especially against competitors like AstraZeneca’s camizestrant.
Want More Context? 🔎
Loading PerspectiveSplit analysis...
